Shanghai Haohai Biological Technology : Haohai Biological Technology to be included in Shanghai-Hong Kong Stock Connect, effective of February 1
February 17, 2021 at 11:29 am EST
Share
Haohai Biological Technology(688366.SH,06826.HK)will be included in Shanghai Stock Connect and Hong Kong Stock Connect as of February 1!
On January 22, Shanghai Stock Exchange issued its newly-revised 'Measures of Shanghai Stock Exchange for Implementation of Shanghai-Hong Kong Stock Connect Business', effective as of February 1, 2021. The revision mainly consists of two aspects: firstly, specifying the appropriateness requirements for trading of SSE STAR Market shares by Shanghai Stock Connect investors, i.e., only institutional professional investors that meet the requirements defined in related rules of Hong Kong can participate in STAR Market stock trading through Shanghai Stock Connect; secondly, H shares of A+H share companies listed on Shenzhen Stock Exchange are included in the scope of Hong Kong Stock Connect stocks under the SH-HK Stock Connect.
Meanwhile, as of February 1, STAR Market stocks that are constituent stocks of SSE 180 Index and SSE 380 Index and A shares of A+H share companies will be officially included in the scope of stocks of Shanghai Stock Connect; H shares of A+H share companies listed on the STAR Market and H shares of A+H share companies listed on Shenzhen Stock Exchange will be officially included in the scope of Hong Kong Stock Connect stocks.
This also means that Haohai Biological Technology will be included in both Shanghai Stock Connect and Hong Kong Stock Connect as of February 1. As a high-tech biopharmaceutical company that has been growing up benefiting from the opening-up policies of capital markets, Haohai Biological Technology was successfully listed on the Main Board of The Stock Exchange of Hong Kong Ltd on April 30, 2015 and then listed on the STAR Market on October 30, 2019, becoming the first biopharmaceutical company to be listed on 'H+STAR Market'. In the future, Haohai Biological Technology will continue upholding its business philosophy of 'hard work, innovation and development', create a high-quality listed company on the Chinese capital markets across the board and reciprocate its investors and the wider society with a more outstanding business performance.
Attachments
Original document
Permalink
Disclaimer
Shanghai Haohai Biological Technology Co. Ltd. published this content on 25 January 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 17 February 2021 16:29:08 UTC.
Shanghai Haohai Biological Technology Co., Ltd. is a China-based company principally engaged in biological technology-related businesses. The businesses of the Company include the manufacture and sales of biological and medical hyaluronate, the research and development of biological engineering and pharmaceutical products and the provision of related services. Its products include orthopedics products, medical aesthetics and wound care products, ophthalmology products and anti-adhesion and hemostasis products, among others. Orthopedics products include sodium hyaluronate injection, medical chitosan and medical sodium hyaluronate gel. Medical aesthetics and wound care products include recombinant human epidermal growth factor (rhEGF), among others. Ophthalmology products include ophthalmic viscoelastic devices and lubricant eye drops. Anti-adhesion and hemostasis products include medical collagen sponges, among others. The Company mainly operates businesses in Mainland China.